Zai Lab Ltd (ZLAB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Zai Lab Ltd stock (ZLAB) is currently trading at $18.29. Zai Lab Ltd PS ratio (Price-to-Sales) is 4.35. Analyst consensus price target for ZLAB is $38.47. WallStSmart rates ZLAB as Sell.
- ZLAB PE ratio analysis and historical PE chart
- ZLAB PS ratio (Price-to-Sales) history and trend
- ZLAB intrinsic value — DCF, Graham Number, EPV models
- ZLAB stock price prediction 2025 2026 2027 2028 2029 2030
- ZLAB fair value vs current price
- ZLAB insider transactions and insider buying
- Is ZLAB undervalued or overvalued?
- Zai Lab Ltd financial analysis — revenue, earnings, cash flow
- ZLAB Piotroski F-Score and Altman Z-Score
- ZLAB analyst price target and Smart Rating
Zai Lab
📊 No data available
Try selecting a different time range
Smart Analysis
Zai Lab Ltd (ZLAB) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Zai Lab Ltd (ZLAB) Key Strengths (1)
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Zai Lab Ltd (ZLAB) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Premium valuation at 4.3x annual revenue
Fairly priced relative to book value
Solid revenue growth at 17.00% per year
Moderate institutional interest at 30.04%
Zai Lab Ltd (ZLAB) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 7.0/10) while 7 fall into concern territory (avg 3.1/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Market Cap.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (4.35), Price/Book (2.80) suggest expensive pricing. Growth concerns include Revenue Growth at 17.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -22.60%, Operating Margin at -54.40%, Profit Margin at -38.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -22.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 17.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ZLAB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ZLAB's Price-to-Sales ratio of 4.35x sits near its historical average of 4.54x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 7% below its historical high of 4.68x set in Mar 2026, and 0% above its historical low of 4.35x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Zai Lab Ltd (ZLAB) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Zai Lab Ltd is a strong growth company balancing expansion with improving profitability. Revenue reached 460M with 17% growth year-over-year. The company is currently unprofitable, posting a -38.2% profit margin.
Key Findings
The company is unprofitable with a -38.2% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -26M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Zai Lab Ltd.
Bottom Line
Zai Lab Ltd offers an attractive blend of growth (17% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(47 last 3 months)
| Insider | Type | Shares |
|---|---|---|
GAYNOR, RICHARD Director | Buy | +1,731 |
| Insider | Type | Shares |
|---|---|---|
AMADO, RAFAEL See Remarks | Sell | -10,000 |
| Insider | Type | Shares |
|---|---|---|
AMADO, RAFAEL See Remarks | Sell | -10,787 |
Data sourced from SEC Form 4 filings
Last updated: 10:00:57 AM
About Zai Lab Ltd(ZLAB)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
China
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is headquartered in Shanghai, China.